Drug Trial Radar · NCT07176689
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Sep 17, 2025
Primary completion
Feb 26, 2031
Study completion Feb 26, 2031
Sponsor
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
Conditions
- Desmoid Tumor
- Aggressive Fibromatosis
Interventions
NirogacestatDrug
Nirogacestat oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ovarian function recovery rate of ovarian toxicity (OT) treatment-emergent adverse events (TEAEs)Time frame: Up to 24 cycles (each cycle is 28 days) of treatment and up to 2 years in the Clinical Follow-up Period
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc (CUSL)
Brussels, Belgium · Recruiting
Universitaetsmedizin Mannheim
Mannheim, Germany · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Italy · Recruiting
IRCCS Istituto Ortopedico Rizzoli di Bologna
Bologna, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Milan, Italy · Recruiting
Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale
Naples, Italy · Recruiting
Policlinico Universitario Campus Bio-Medico
Roma, Italy · Recruiting
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Meldola, Forli-Cesena, Italy · Recruiting
La Fondazione e l'Istituto di Candiolo
Candiolo, Torino, Italy · Recruiting
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
Amsterdam, Netherlands · Recruiting
Academisch Ziekenhuis Leiden
Leiden, Netherlands · Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain · Recruiting
Institut Catala d'Oncologia
Barcelona, Spain · Recruiting
Hospital General Universitario Gregorio Maranon
Madrid, Spain · Recruiting
Hospital Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Cambridge University - Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
University College London Hospital
London, United Kingdom · Recruiting
The Royal Marsden NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.